Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma.
Saved in:
| Title: | Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma. |
|---|---|
| Authors: | Li YX; Department of Neurology, Taikang Ningbo Hospital, Ningbo, 315042, China. Zju21918592@163.com., Wang RY; Department of Neurology, Taikang Ningbo Hospital, Ningbo, 315042, China., Hao YL; Department of Neurology, Taikang Ningbo Hospital, Ningbo, 315042, China. |
| Source: | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2025 Dec 17; Vol. 47 (1), pp. 13. Date of Electronic Publication: 2025 Dec 17. |
| Publication Type: | Journal Article; Case Reports; Systematic Review |
| Journal Info: | Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
